

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/841,836
--------------------	------------

Filing Date	April 25, 2001
-------------	----------------

First Named Inventor	Roberts, Bruce L.
----------------------	-------------------

Group Art Unit	1641 1648
----------------	----------------------

Examiner Name	Unassigned Chen
---------------	----------------------------

Attorney Docket Number	GA0229US
------------------------	----------

RECEIVED

SEP 25 2002

TECH CENTER 600/2900

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
SBC	1	WO 95/31187 ✓	11-23-95	McMaster University		
	2					
	3					
	4					
	5					
	6					
	7					
	8					
	9					

**Examiner
Signature**

Stacy B. Chen

Date
Considered


October 30, 2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Use of form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/841,836
Filing Date	April 25, 2001
First Named Inventor	ROBERTS, Bruce L.
Group Art Unit	1641-1648
Examiner Name	Unassigned Chen
Attorney Docket Number	GA0229US

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SBC	10 ✓	BAKER, A. et al., "Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery", Gene Therapy, 1997, 4:773-782	
SBC	11 ✓	de GRUIJL, T. et al., "Targeted Transduction of Human Cutaneous Dendritic Cells In Situ by CD40-Mediated Adenoviral Gene Transfer: A New Approach to Tumor Vaccination", Proceedings of the American Association for Cancer Research, March 2000, 41:217, #1383	
SBC	12 ✓	DIEBOLD, S.S. et al., "Efficient Gene Delivery into Human Dendritic Cells by Adenovirus Polyethylenimine and Mannose Polyethylenimine Transfection", Human Gene Therapy, March 1999, 10:775-786	
SBC	13 ✓	DIEBOLD, S.S. et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells", The Journal of Biological Chemistry, July 1999, 274(27):19087-19094	
SBC	14 ✓	GORDON, Y.J. et al., "Replication of ocular isolates of human adenovirus is serotype-dependent in rabbit corneal organ culture", Current Eye Research, 1991, 10(3):267-271	
SBC	15 ✓	KAPLAN, J.M. et al., "Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector- Encoding Endogenous Tumor-Associated Antigens", The Journal of Immunology, 1999, 163:699-707	
SBC	16 ✓	MULDER, P. et al., "Highly Efficient and Consistent Gene Transfer into Dendritic Cells Utilizing a Combination of Ultraviolet-irradiated Adenovirus and Poly(L-Lysine) Conjugates", Cancer Research, March 1998, 58:956-961	
SBC	17 ✓	SCHEICHER, C. et al., "Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1alpha and interleukin-12p40/p35 and triggers prolonged, efficient antigen presentation", European Journal of Immunology, 1995, 25:1566-1572	
SBC	18 ✓	TILLMAN, B.W. et al., "Maturation of Dendritic Cells Accompanies High-Efficiency Gene Transfer by a CD40- Targeted Adenoviral Vector", The Journal of Immunology, 1999, 162:6378-6383	
SBC	19 ✓	YE, Y.W. et al., "Bioresorbable Microporous Stents Deliver Recombinant Adenovirus Gene Transfer Vectors to the Arterial Wall", Annals of Biomedical Engineering, 1998, 26:398-408	
SBC	20 ✓	ZHONG, L. et al., "Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells", European Journal of Immunology, 1999, 29:964-972	

Examiner
Signature

Hany B Chen

Date
Considered

October 30, 2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.